Most glioblastoma tumors are marked by one or two broad mutation patterns, but about 20 percent of the lethal brain tumors have biomarkers that cannot be identified.

Targeting a protein genome-binding process that directs expression of diverse cancerous genes could be an important new therapy approach for stopping the progression of late-stage prostate cancer,

  In the last post, I identified five stages for successful complex grant development.

Duke team challenges the paradigm about fluid as a symptom of heart failure

When scientists first described the receptors responsible for our sense of smell, they naturally assumed that these chemical sensors resided exclusively in the lining of our noses.

[Video:https://youtu.be/iyOpqBVtSMY] 

OnCore Community News iRIS Community News OnCore and iRIS are Live!

 Innovation Speaker, Tom Insel, MD  

I’ve been thinking a lot lately about processes, particularly how we facilitate development of complex research grants.

The next event in a new presentation series on grants and research will take place May 29.